Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer

1

Introduction

00:00 • 3min

2

The Importance of Immunotherapy in Oncology

02:50 • 2min

3

The Impact of Immune Therapy on Cancer

04:28 • 3min

4

The Long-Term Effects of Immunotherapy on Metastatic Disease

07:22 • 6min

5

The Importance of PDL1 in Breast Cancer

13:17 • 4min

6

The Differences Between IOs and Anti-Pd1 Drugs

17:18 • 3min

7

CTL4 Inhibition in Lung Cancer

20:38 • 6min

8

The High Response Rates in First Line Chemotherapy

26:27 • 3min

9

Tusa-Mitumab Ref Tansin: A Targeted Antibody Drug Conjugate

29:44 • 5min

10

The Need for New Strategies for Tumor Treatment

34:33 • 5min

11

The Toxicity Profile of Systemic Therapy for Metastatic Cancer

39:23 • 2min

12

The Role of Neoadjuvant Therapy in Lung Cancer

41:05 • 3min

13

Neoadjuvant or Adjuvant Immunotherapy?

43:47 • 2min

14

The Future of Adjuvant Therapy in Breast Cancer

46:14 • 5min

15

The Relationship Between Benefit and PDL1 Expression in the Pearls Trial

50:54 • 2min

16

The Importance of PDL1 Expression in Adjuvant Therapy

52:27 • 4min

17

The Pacific Trial: A Step Forward in the Adjuvant Setting

56:12 • 5min

18

CTDNA and Colorectal Cancer

01:00:52 • 2min